Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 4/20 | 0.57 |
| ▸ | REN | P00797 | 10/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18257575 | 0.90 | CTSD (0.57) | CTSDRENCTSSCTSKCTSL | |
| SCHEMBL18257544 | 0.90 | CTSD (0.57) | CTSDRENCTSSCTSKCTSL | |
| SCHEMBL18257559 | 0.88 | CTSD (0.56) | CTSDRENCTSSCTSKCTSL | |
| SCHEMBL18257555 | 0.88 | CTSD (0.56) | CTSDRENCTSSCTSKCTSL | |
| SCHEMBL7139684 | 0.85 | CTSS (0.49) | CTSDRENCTSSCTSKCTSL | |
| SCHEMBL7137824 | 0.84 | CTSK (0.48) | CTSDRENCTSSCTSKCTSL | |
| SCHEMBL7138103 | 0.83 | CTSS (0.51) | CTSDRENCTSSCTSKCTSL | |
| SCHEMBL7139680 | 0.83 | CTSS (0.43) | CTSDRENCTSSCTSKCTSL | |
| SCHEMBL7139828 | 0.82 | CTSK (0.46) | CTSDRENCTSSCTSKKMT2A | |
| SCHEMBL29612215 | 0.82 | CTSD (0.61) | CTSDRENCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CTSD 18/4885REN 136/4885CTSS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.